Locations
Conditions
Treatments
Institutions
Resources
For researchers
About us
Clinical trials
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Apply
Rilvegostomig & Fluoropyrimidine & Trastuzumab Deruxtecan
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Basic information
Step 1/5
Provide your basic information
Age
ZIP code
Back
Next step